Other compounds

Ostarine: molecular data, studies & sources

Ostarine is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C19H14F3N3O3
Molecular weight (MW): 389.33 g/mol
ChEMBL ID: CHEMBL1738889
Record title: Enobosarm

Formula and molecular weight are calculated from the ChEMBL parent structure. Salts, hydrates and formulation excipients change the supplied material; confirm the identity on the batch certificate.

Source: ChEMBL CHEMBL1738889 · retrieved 2026-10-01

2D molecular structure for Ostarine, ChEMBL CHEMBL1738889 — 2D depiction rendered with RDKit from the ChEMBL structure. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: Not supplied
InChIKey: JNGVJMBLXIUVRD-SFHVURJKSA-N
SMILES: C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1

Machine-readable ChEMBL source

Identifiers

InChIKey: JNGVJMBLXIUVRD-SFHVURJKSA-N

Calculated molecular descriptors

Monoisotopic (exact) mass	389.0987 Da
Heavy atoms	28
Hydrogen-bond donors	2
Hydrogen-bond acceptors	5
Rotatable bonds	5
Topological polar surface area	106.1 Å²
Calculated logP (Crippen)	3.22
Rings	2
Stereocenters	1
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID: CHEMBL1738889
Modality: Small molecule
Highest clinical stage: Phase 3
Record name: ENOBOSARM

Mechanism of action

Androgen Receptor modulator · target: androgen receptor (AR)

Synonyms, codes and trade names

Trade and brand names: Ostarine
Synonyms and development codes: Enobosarm · GTX-024 · MK-2866

Identity check: Exact name, synonym or trade-name match. Source: ChEMBL CHEMBL1738889 via Amass DrugCore · retrieved 2026-10-01

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Ostarine as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

17 registered studies matched, 1 currently active or recruiting, 9 with results posted on ClinicalTrials.gov.

By highest phase: Phase 3 · 4Phase 2 · 12Phase 1 · 1
By registry status: Completed · 9Terminated · 4Withdrawn · 3Active Not Recruiting · 1

Study	Phase · status	Conditions	Sponsor · size
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998 · start 2026-03-26 · primary completion 2027-10	Phase 2Active Not Recruiting	Obesity & Overweight · Mobility Disability · HOMA-IR	Veru Inc.239 participants
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458 · start 2024-04-29 · primary completion 2025-04-11	Phase 2Completed	Muscle Loss · Obesity	Veru Inc.168 participants
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerNCT05065411 · start 2022-04-11 · primary completion 2023-10-19	Phase 3TerminatedWhy stopped: Business decision	Metastatic Breast Cancer	Veru Inc.5 participants
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 · start 2021-10-12 · primary completion 2024-01-09	Phase 3TerminatedWhy stopped: Business decision	Metastatic Breast Cancer	Veru Inc.52 participants
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinenceNCT03566290 · start 2018-06-28 · primary completion 2018-09-21	Phase 2WithdrawnWhy stopped: Development of investigational product was halted.	Stress Urinary Incontinence	GTxEnrollment not listed
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary IncontinenceNCT03508648 · start 2018-05-28 · primary completion 2018-09-21	Phase 2WithdrawnWhy stopped: Lack of efficacy from primary study	Stress Urinary Incontinence	GTxEnrollment not listed
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary IncontinenceNCT03241342 · start 2017-08-21 · primary completion 2018-09-21	Phase 2CompletedResults posted 2020-11-12	Stress Urinary Incontinence	GTx491 participants
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerNCT02971761 · start 2017-06-01 · primary completion 2020-10-28	Phase 2CompletedResults posted 2022-06-10	Androgen Receptor Positive · Estrogen Receptor Negative · HER2/Neu Negative · Metastatic Triple-Negative Breast Carcinoma · Progesterone Receptor Negative · Stage IV Breast Cancer AJCC v6 and v7	City of Hope Medical Center18 participants
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast DensityNCT03264651 · start 2017-02-01 · primary completion 2018-03-21	Phase 1Completed	Mammographic Density	Havah Therapeutics Pty Ltd9 participants
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body MassNCT02746328 · start 2016-04 · primary completion 2018-02	Phase 2WithdrawnWhy stopped: Investigational drug development was halted.	ER+ and AR+ Breast Cancer	GTxEnrollment not listed

Show 7 more registered studies

Study	Phase · status	Conditions	Sponsor · size
GTx-024 as a Treatment for Stress Urinary Incontinence in WomenNCT02658448 · start 2016-01 · primary completion 2018-06	Phase 2CompletedResults posted 2021-02-01	Stress Urinary Incontinence	GTx19 participants
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerNCT02463032 · start 2015-08 · primary completion 2019-03	Phase 2CompletedResults posted 2020-12-09	ER+ and AR+ Breast Cancer	GTx136 participants
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)NCT02368691 · start 2015-06 · primary completion 2017-09-22	Phase 2TerminatedResults posted 2020-10-30Why stopped: Lack of Efficacy	Triple Negative Breast Cancer	GTx32 participants
Phase II Study of GTx024 in Women With Metastatic Breast CancerNCT01616758 · start 2013-04 · primary completion 2014-06	Phase 2TerminatedResults posted 2024-03-08	Metastatic Breast Cancer	GTx22 participants
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)NCT01355484 · start 2011-07 · primary completion 2013-05	Phase 3CompletedResults posted 2016-03-03	Muscle Wasting · Non Small Cell Lung Cancer	GTx321 participants
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumNCT01355497 · start 2011-07 · primary completion 2013-05	Phase 3CompletedResults posted 2020-11-09	Muscle Wasting · Non-Small Cell Lung Cancer	GTx330 participants
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.NCT00467844 · start 2007-05 · primary completion 2008-09	Phase 2CompletedResults posted 2013-02-21	Cachexia	GTx159 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Ostarine, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Research publication · design requires review
Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine).
Kintz P, Gheddar L, Paradis C et al. · Toxics · 2021
PMID 34678947 · DOI: 10.3390/toxics9100251
Research publication · design requires review
Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activityand Tissue Selectivity.
Dart DA, Kandil S, Tommasini-Ghelfi S et al. · Molecular cancer therapeutics · 2018
PMID 29895558 · DOI: 10.1158/1535-7163.MCT-18-0037
Review · secondary evidence
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J, Prado CM, Johnston MA et al. · Current oncology reports · 2016
PMID 27138015 · DOI: 10.1007/s11912-016-0522-0 · Registration NCT01355484, NCT01355497
Research publication · design requires review
A Computational and In Vitro Appraisal of Ostarine to Target Androgen Receptor in Glioma C6 Cells.
Sharma S, Saini S, Chadha VD et al. · Cell biochemistry and biophysics · 2025
PMID 40514634 · DOI: 10.1007/s12013-025-01797-0
Preclinical / laboratory research
Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.
Roch PJ, Henkies D, Carstens JC et al. · Frontiers in endocrinology · 2020
PMID 33042018 · DOI: 10.3389/fendo.2020.556581
Preclinical / laboratory research
Ostarine does not enhance the metabolic effect of exercise in obese rats.
Leciejewska N, Pruszynska-Oszmalek E, Sassek M et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2023
PMID 37865959 · DOI: 10.26402/jpp.2023.4.06
Case report
Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator.
Bedi H, Hammond C, Sanders D et al. · ACG case reports journal · 2021
PMID 34368386 · DOI: 10.14309/crj.0000000000000518
Case report
Interest of nail clipping tests to discriminate a tail end of a doping regimen from a contamination in case of challenging an adverse analytical finding: Case reports involving ostarine.
Kintz P, Gheddar L, Ameline A et al. · Drug testing and analysis · 2023
PMID 37718535 · DOI: 10.1002/dta.3577

Ostarine supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

ChEMBL compound record CHEMBL1738889 — chemical identity and structure.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.